Clinical Trial Update: Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy, safety and tolerability of canakinumab (ACZ885) in patients with pulmonary sarcoidosis completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcoidosis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Sarcoidosis | Phase 2 | Status: COMPLETED | Results posted: 2020-03-16